Cell lines are critical reagents for much of cancer research. One might intuitively imagine that cancer cells, with their in vivo selective growth advantage, would be relatively easy to establish in culture. However, generating cancer cell lines is surprisingly difficult. Athymic (""""""""nude"""""""") and severe combined immunodeficient (SCID) mice are valuable tools that support human cancer cell growth. When the cancer is harvested for in vitro cell line production, fibroblasts and other stromal cells commonly overgrow the culture dish and in most cases prevent isolation of the malignant cells. The study of invasion and metastasis (hallmarks of cancer) is similarly hindered by the inability to recover small numbers of cancer cells that have completed the process. To circumvent these problems, we are generating immunodeficient mice that are hprt defective, and have already constructed a nude hprt-null mouse. Similar to other immunodeficient mice, they will support growth of many xenografted cancers. During tumor growth, mouse cells replace the human stromal cells. When we wish to recover the human cells, we will eliminate the mouse stromal cells by growing the culture in the classic selective media, HAT. In this proposal, we plan to: generate SCID hprt-null mice, demonstrate superiority of the biochemically defective mice for cell line production, and demonstrate enhanced recovery of cells from spontaneous metastases.
Specific Aim #1 : Generate biochemically selectable immunodefective mice designed for human cancer cell recovery. Specifically, generate SCID hprt-null mice.
Specific Aim #2 : Document superiority of the hprt-null mice over standard nude and SCID mice. Specifically, document mouse stromal cell replacement and isolate pure populations of human cancer cell lines from xenografts established from patient-derived primary cancers (breast, prostate, lung, pancreatic and glial cancers). Compare recovery with and without stromal cell supplementation.
Specific Aim #3 : Document utility in recovering small numbers of metastatic cancer cells. Specifically, determine recovery efficiency from spiked samples, and isolate organ-specific metastases from experimental metastases and from spontaneous metastases after orthotopic implantation. Mice will be deposited at Jackson Labs for distribution to investigators at non-profit institutions, including the NIH.

National Institute of Health (NIH)
National Cancer Institute (NCI)
Research Project (R01)
Project #
Application #
Study Section
Tumor Microenvironment Study Section (TME)
Program Officer
Jhappan, Chamelli
Project Start
Project End
Budget Start
Budget End
Support Year
Fiscal Year
Total Cost
Indirect Cost
Johns Hopkins University
Schools of Medicine
United States
Zip Code
Kamiyama, Hirohiko; Rauenzahn, Sherri; Shim, Joong Sup et al. (2013) Personalized chemotherapy profiling using cancer cell lines from selectable mice. Clin Cancer Res 19:1139-46
Jones, Sian; Li, Meng; Parsons, D Williams et al. (2012) Somatic mutations in the chromatin remodeling gene ARID1A occur in several tumor types. Hum Mutat 33:100-3
Chen, Guoli; Olson, Matthew Theodore; O'Neill, Alan et al. (2012) A virtual pyrogram generator to resolve complex pyrosequencing results. J Mol Diagn 14:149-59
Cui, Yunfeng; Brosnan, Jacqueline A; Blackford, Amanda L et al. (2012) Genetically defined subsets of human pancreatic cancer show unique in vitro chemosensitivity. Clin Cancer Res 18:6519-30
Wang, Qing; Chaerkady, Raghothama; Wu, Jian et al. (2011) Mutant proteins as cancer-specific biomarkers. Proc Natl Acad Sci U S A 108:2444-9
Vincent, Audrey; Omura, Noriyuki; Hong, Seung-Mo et al. (2011) Genome-wide analysis of promoter methylation associated with gene expression profile in pancreatic adenocarcinoma. Clin Cancer Res 17:4341-54
Wright, Chapman M; Wright, R Clay; Eshleman, James R et al. (2011) A protein therapeutic modality founded on molecular regulation. Proc Natl Acad Sci U S A 108:16206-11
Lin, Ming-Tseh; Tseng, Li-Hui; Kamiyama, Hirohiko et al. (2010) Quantifying the relative amount of mouse and human DNA in cancer xenografts using species-specific variation in gene length. Biotechniques 48:211-8
Hector, Alvarez; Montgomery, Elizabeth A; Karikari, Collins et al. (2010) The Axl receptor tyrosine kinase is an adverse prognostic factor and a therapeutic target in esophageal adenocarcinoma. Cancer Biol Ther 10:1009-18
Kamiyama, Hirohiko; Kamiyama, Mihoko; Hong, Seung-Mo et al. (2010) In vivo and in vitro propagation of intraductal papillary mucinous neoplasms. Lab Invest 90:665-73

Showing the most recent 10 out of 12 publications